434 related articles for article (PubMed ID: 16033844)
1. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
2. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
3. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
4. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
5. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
6. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
Ochakovskaya R; Osorio L; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jun; 7(6):1505-10. PubMed ID: 11410483
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
8. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
10. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
Stastny JJ; Das Gupta TK
Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
12. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
15. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
16. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Dillman RO; Johnson DE; Ogden J; Beidler D
Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
18. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
19. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.
Chang CH; Sapra P; Vanama SS; Hansen HJ; Horak ID; Goldenberg DM
Blood; 2005 Dec; 106(13):4308-14. PubMed ID: 16109781
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]